Last reviewed · How we verify
PIPERACILLIN SODIUM
At a glance
| Generic name | PIPERACILLIN SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
Common side effects
- Diarrhea
- Constipation
- Nausea
- Headache
- Insomnia
- Fever
- Rash
- Pruritus
- Candidiasis
- Vomiting
- Dyspepsia
- Abdominal pain
Key clinical trials
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment (PHASE2)
- SYN-004 Safety and Tolerability in Allo-HCT Subjects (PHASE1, PHASE2)
- Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity (PHASE4)
- Aminoglycosides in Early Sepsis (PHASE4)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PIPERACILLIN SODIUM CI brief — competitive landscape report
- PIPERACILLIN SODIUM updates RSS · CI watch RSS